Rome, Jan 23.- Through a pilot clinical study, Italian experts were able to identify a possible early biomarker to diagnose Parkinson's disease, the National Research Council (CNR) reported here.
In the same way, it represents a pharmacological route for potentially useful therapies against this condition, according to the entity when informing in a statement about the investigation, the results of which were published in the medical journal Movement Disorders.
The CNR Institute of Biochemistry and Cell Biology intervened in the investigation, together with the University of Rome, La Sapienza and that of Tor Vergata, the text says.
The study carried out on blood samples from 31 Parkinson's patients showed for the first time an increase in the chemokine prokinethicin 2 (PK2), which suggests a possible protective role, the source indicates.
He also noted that "for the first time it was shown that serum levels of PK2 increase significantly compared to healthy controlled subjects." According to Cinzia Severini, a researcher at the Institute, the correlation between the increase in serum PK2 and two markers of neurodegeneration in the cerebrospinal fluid of the same patients, such as beta amyloid1-42 and lactate, was particularly interesting.
He clarified that, in particular, this increase in the peptide may indicate a protective effect of chemokine against pathology at the level of neuronal synapses and the deposition of amyloid or senile plaques, common events in both Parkinson's and Alzheimer's disease.
Severini specified that such findings must be confirmed in a larger study, both in number and patient characteristics, in addition to evaluating more biological tissues.
It is, he pointed out, "to fully understand the role of PK2 in Parkinson's disease, thus opening the way to possible clinical developments focused on this peptide." (Text and photo: PL)